ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IXI Ixico Plc

7.00
0.00 (0.00%)
24 May 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 7.00 8,205 08:00:00
Bid Price Offer Price High Price Low Price Open Price
6.75 7.25 7.00 7.00 7.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
  -
Last Trade Time Trade Type Trade Size Trade Price Currency
08:04:53 O 8,205 7.19 GBX

Ixico (IXI) Latest News

Ixico (IXI) Discussions and Chat

Ixico Forums and Chat

Date Time Title Posts
25/5/202412:05Ixico PLC378
28/4/202112:03IXICO324

Add a New Thread

Ixico (IXI) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Ixico (IXI) Top Chat Posts

Top Posts
Posted at 27/1/2024 12:35 by 40 fathoms
Well Giulio is going, it was clear all the fight had gone out of him so it is not a huge surprise as he has not been very effective but has been very, very expensive. It is going to take a year for him to leave and there will have to overlap with another expensive (but hopefully less so) CEO, so there will be double costs for a while.

CFO also needs to be replaced with one that costs half as much and then you would have clean foundations and things can start to look a lot better. Also, unless they are able to sign some large, new, contracts and or cut their R&D spend very soon then they are going to need more cash.

With the right CEO and a much less ambitions strategy it would not be hard to get to a position where it is making a sustanible EBIT of GBP 2 or GBP 3 million per year. That is worth a share price of 50p in my view, provided they do not increase the share count. They also need to give up on AD and ARIA as they are not in the race. Double down on Huntingdon's and pick up the focus on some of the other less competitive CNS indications.

If we see this or a similar strategy put in place then I am a buyer. If this does not happen this is going to bump around between 8p and 15p for as far as the eye can see.
Posted at 26/1/2024 04:22 by up4itt
The selling is attributable to the fact that I had just bought in prior to the drop in the share price. The correlation seldom fails.
Posted at 08/12/2023 11:02 by jimtech
Guilio was obviously frustrated with the "harsh" lowly company valuation.
But then there is not much to get excited about if they are expecting a flat 2024 so share price may well sink further.
I thought the fundraising comments were theoretical but you are right, as you point out, they were not dismissed out of hand.
Posted at 23/6/2023 12:27 by 40 fathoms
@Jane Deer.

Any market surveillance in AD would be to identify ARIA H and ARIA E in patients (not as a diagnostic) that are given monoclonal antibodies that clear Amyloid Beta. The PDUFA date for a full approval of Lecanamab is 6th July and at that point we will know, if approved, what requirements the FDA will impose for market surveillance. If they were to win anything in the near term, this is the opportunity, particularly as they have provided the Assessa platform for progressive multifocal leukoencephalopathy (PML)in conjunction with Biogen, who is also the co-developer of Lecanamab. So you would think this would represent the most likely live opportunity.

That said Eisai and Biogen have been preparing for this approval and subsequent role out for years now and have put in place the infrastructure to support and monitor this rollout. I would be very surprised indeed, if now at this late stage, they announce something exclusive with Ixico for Lecanamab. As you might be aware, last year Adhuelm also a Biogen AD Thereaputic, was approved by the FDA last year. Although it has been a complete disaster commercially, there was post market surveillance requirements imposed by the FDA and I note that their was no post market surveillance contract for Ixico.

There is a possibility they could win something with Lilly for Donanemab, which will likely be approved and rolled out 1H next year. However, as with Biogen/Eisai, given the scale of preparation that goes in to a drug launch of this type, I think we would know by now if they were likely to gain a contract here.

My feeling is in the longer run they might pick up some work in this regard by contracting with individual hospitals or health systems. However, this is likely 2 or more years away and it will be slow to build, in particular as they have no healthcare sales network.

While a rabbit could be pulled from the hat, I think the reality is that the next 12 to 18 months are going to be difficult for Ixico. If they can shepherd their cash then there is a good possibility of salvation after that. If they cannot, the board and the C suite are crazily paid, then they are going to need to raise a decent (in comparison to market cap) amount of cash with all of the share price pain that entails.
Posted at 10/5/2023 16:12 by halfpenny
IXI expected to exceed expectations as demand for its AI Product is huge.

Share price needs to get above 33p to reduce takeover target potential.

Great to add at these levels which wont stay at this level for long. As they say cheap as chips after the results today. Rapid rises in the pipeline. I say add if you can at these ridiculous levels.

Happy Days Ahead
Posted at 10/5/2023 08:29 by halfpenny
Now IXI have a strong platform with cash in the bank, AI products and a strong order book for 2023 and great outlook for 2024.

IXI with strong AI products being released puts them ahead of the market.

Investors now circulating IXI at these levels.

Future looking great for IXI.
Posted at 24/4/2023 12:45 by halfpenny
IXI now likely being pursued by a couple on investors who missed out on Medica Group Plc today.

Investors now circulating IXI at these levels. Only large deals with a share price above 33p can keep them away.

Future looking great for IXI.
Posted at 04/4/2023 15:15 by cliffpeat
@halfpenny

Can you tell us the source of your information regarding future orders/"great deals" and which of the income streams they relate to?

Do you have a steer on trials coming on line - or potential AI analytics demand - or the like?

And the price increases you refer to - are these related to what IXI charges customers or it the share price?
Posted at 04/4/2023 08:28 by halfpenny
Another Order for IXI so expect plenty more in the pipeline. Takeover target at these levels so needs rapid orders. Interesting times ahead so got more at these levels.

IXI have a huge increasing interest of its AI Products , is this when the company orders and sales pipeline grows quickly.

Maybe a Takeover still on the cards as IXICO price levels are attractive at the current levels.

IXI future is very bright so get ready for dramatic price increases ahead.

Following yesterday RNS Expect further RNS soon on great Deals.
Posted at 21/4/2022 07:33 by tomboyb
IXICO plc New Contract Win
21/04/2022 7:00am
UK Regulatory (RNS & others)

Ixico (LSE:IXI)
Intraday Stock Chart

Thursday 21 April 2022

Click Here for more Ixico Charts.
TIDMIXI

RNS Number : 8126I

IXICO plc

21 April 2022

21 April 2022

IXICO plc

("IXICO" or the "Company")

Contract award with a new client for a Huntington's Disease ('HD') trial worth circa GBP800,000

IXICO plc (AIM: IXI), the neuroimaging Contract Research Organisation (CRO) delivering advanced AI analytical insights in neuroscience, is pleased to announce it has been selected by a new client to support its global prospective observational study to assess participants for the early detection of HD. HD is a rare, inherited disease that causes the progressive breakdown of nerve cells in the brain affecting movement, mood and thinking abilities.

The new client is a biotech company specialized in gene therapy for neurodegenerative and other genetic diseases. IXICO will provide a range of its imaging CRO and advanced analytics services across approximately 2.5 years.

Having combined AI imaging biomarker analysis across many HD trials, together with centralised CRO services, IXICO is continuously enhancing its validated disease-optimised advanced analytics technology for this indication. This new contract follows our recent presentation on our new deep learning-based platform, IXIQ.Ai, at the Annual HD Therapeutics Conference in Palm Springs, a technology which IXICO will be applying to this trial. This, together with the ability to deliver its services through our proprietary TrialTracker imaging data management platform, makes IXICO the clear partner of choice for this study.

Giulio Cerroni, Chief Executive Officer of IXICO, commented : " With no current cure for Huntington's, nor interventions that slow disease progression, HD is a devastating rare neurological condition with significant unmet medical needs. We are delighted to further extend our client base and support identifying new insights into this challenging rare neurodegenerative disease. We are committed to ensuring that our validated machine learning AI data analytics, combined with the quality assurance of our TrialTracker platform, enable clients to unlock new insights into disease progression and drug development."

For further information please contact:
Ixico share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock